Editorial on HIT series on emergent CAR T-cell toxicities

Helen E Heslop
2023
Conflict of interest: COI declared -see note COI notes: H.E.H. has equity in Allovir and Marker Therapeutics and share options in Fresh Wind Biotherapeutics and Coregen, has served on advisory boards for Tessa Therapeutics and GSK and received research support from Athenex and Tessa Therapeutics.
doi:10.1182/blood.2023020228 pmid:36928098 fatcat:54fozejkxvg77gtl2ggss56dwi